Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Prostate Cancer

Free Subscription 16.02.2026 2 BJU Int 3 BMC Cancer 2 BMC Urol 1 Cancer 1 Cancer Lett 2 Eur Radiol 2 Eur Urol 3 Int J Urol 1 J Magn Reson Imaging 2 J Nucl Med 4 J Urol 1 Lancet Oncol 1 Mod Pathol 1 Nat Rev Urol 1 PLoS One 3 Prostate 1 Radiol Imaging Cancer 8 Urology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BJU Int

1. JANG JY, Lee JH, Pyo H, Park W, et al
   Risk of rectal bleeding with endorectal balloon use after hypofractionated intensity-modulated radiotherapy for prostate cancer.
   BJU Int. 2026 Feb 13. doi: 10.1111/bju.70175.
   PubMed         Abstract available
   
   
2. VEERASATIAN T, Arunsan P, Rattanapitoon SK, Rattanapitoon NK, et al
   Beyond sensitivity: artificial intelligence and micro-ultrasonography in prostate cancer detection.
   BJU Int. 2026 Feb 12. doi: 10.1111/bju.70112.
   PubMed        
   
   

   
   BMC Cancer

3. YU C, Wen Y, Li Y, Song B, et al
   Deciphering the eRNA landscape and revealing target aberrant pathways in prostate cancer.
   BMC Cancer. 2026 Feb 10. doi: 10.1186/s12885-026-15675.
   PubMed         Abstract available
   
   
4. BIAN L, Liu F, Huang X, Peng Y, et al
   Noninvasive preoperative risk stratification of prostate cancer via a foundational model based deep learning with PSMA PET/CT.
   BMC Cancer. 2026 Feb 9. doi: 10.1186/s12885-026-15715.
   PubMed        
   
   
5. LI G, Li B, Zhang X, Jia J, et al
   Prognostic value of systemic immune-inflammation index and prognostic nutritional index in advanced prostate cancer: development and validation of a comprehensive nomogram.
   BMC Cancer. 2026 Feb 9. doi: 10.1186/s12885-026-15701.
   PubMed        
   
   

   
   BMC Urol

6. ZHANG Y
   Migration of radioactive seeds to the paravertebral venous system after prostate cancer brachytherapy: a case series and literature review.
   BMC Urol. 2026 Feb 14. doi: 10.1186/s12894-026-02081.
   PubMed        
   
   
7. OZKAN S, Borekoglu A
   Fasting blood glucose to HDL-C ratio as a potential biomarker for prostate cancer risk classification.
   BMC Urol. 2026;26:43.
   PubMed         Abstract available
   
   

   
   Cancer

8. MCKAY RR, Maughan BL, Morgans AK, Shore ND, et al
   Evolving strategies in prostate cancer: Emerging approaches and unmet needs from the Bridging the Gaps in Prostate Cancer expert panel.
   Cancer. 2026;132:e70304.
   PubMed         Abstract available
   
   

   
   Cancer Lett

9. SHIGETA K, Takamori S, Ozawa H, Haratake N, et al
   M1C Mediates LINE-1 Transcription in PARP Inhibitor-Treated Prostate Cancer Cells.
   Cancer Lett. 2026 Feb 12:218320. doi: 10.1016/j.canlet.2026.218320.
   PubMed         Abstract available
   
   

   
   Eur Radiol

10. VAN DEN KROONENBERG DL, Postema AW, Beerlage HP, Oddens JR, et al
    Reply to the Letter to the Editor: Evaluation of an artificial intelligence model based on multiparametric transrectal ultrasound for localizing clinically significant prostate cancer by simulation of targeted biopsies.
    Eur Radiol. 2026 Feb 10. doi: 10.1007/s00330-026-12342.
    PubMed        
    
    
11. BARENTSZ J, Immerzeel J, van der Leest M, Cornel E, et al
    Letter to the Editor: Evaluation of an artificial intelligence model based on multiparametric transrectal ultrasound for localising clinically significant prostate cancer by simulation of targeted biopsies.
    Eur Radiol. 2026 Feb 10. doi: 10.1007/s00330-026-12339.
    PubMed        
    
    

    
    Eur Urol

12. BARLETTA F, Mercinelli C, Montorsi F, Gandaglia G, et al
    Re: Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer.
    Eur Urol. 2026 Feb 9:S0302-2838(26)00026-6. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    
13. VITI A, Scuderi S, Briganti A, Gandaglia G, et al
    Re: Optimal Duration of Androgen Deprivation Therapy with Definitive Radiotherapy for Localized Prostate Cancer. A Meta-analysis.
    Eur Urol. 2026 Feb 11:S0302-2838(26)00029-1. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    

    
    Int J Urol

14. CHEN W, Yoshida S, Yajima S, Tanabe K, et al
    Delayed Survival Benefit of Enzalutamide Plus Radium-223 in Metastatic Castration-Resistant Prostate Cancer: A Time-Dependent Analysis of Reconstructed Individual Patient Data From the PEACE-3 Trial.
    Int J Urol. 2026;33:e70376.
    PubMed         Abstract available
    
    
15. DAGLI I, Canbolat MZ, Uzel T, Cayirli A, et al
    Local Anesthetic Transperineal Prostate Biopsy: Does It Affect Uroflowmetry Results.
    Int J Urol. 2026;33:e70377.
    PubMed         Abstract available
    
    
16. TAKAHARA K, Takeuchi A, Saruta M, Yoshizawa A, et al
    Treatment Strategies for Metastatic Castration-Sensitive Prostate Cancer: Current Evidence and Future Directions.
    Int J Urol. 2026;33:e70375.
    PubMed         Abstract available
    
    

    
    J Magn Reson Imaging

17. JOHNSON PM, Umapathy L, Gigax B, Rossi JK, et al
    Artificial Intelligence in Prostate MRI: Addressing Current Limitations Through Emerging Technologies.
    J Magn Reson Imaging. 2025 Dec 5. doi: 10.1002/jmri.70189.
    PubMed         Abstract available
    
    

    
    J Nucl Med

18. MOGENSEN AW, Torp-Pedersen C, Norgaard M, Petersen LJ, et al
    Biochemical Recurrence-Free Survival After Radical Prostatectomy in Patients with High-Risk Prostate Cancer: A Nationwide Study of PSMA PET/CT Versus Conventional Imaging.
    J Nucl Med. 2026 Feb 12:jnumed.125.271423. doi: 10.2967/jnumed.125.271423.
    PubMed         Abstract available
    
    
19. NIKITAS J, Holzgreve A, Juarez J, Kimura K, et al
    Phase 2 Prospective Trial of Retreatment with [(177)Lu]Lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration-Resistant Prostate Cancer-RE-LuPSMA.
    J Nucl Med. 2026 Feb 12:jnumed.125.271231. doi: 10.2967/jnumed.125.271231.
    PubMed         Abstract available
    
    

    
    J Urol

20. LAWEN T, Garcia RS, Smith MT, Pyo J, et al
    Low Testosterone Levels and Grade Group Progression Among Localized Prostate Cancer Patients on Active Surveillance: A Retrospective Cohort Study.
    J Urol. 2026 Feb 9:101097JU0000000000004986. doi: 10.1097/JU.0000000000004986.
    PubMed         Abstract available
    
    
21. SCHELLHAMMER PF
    Letter: Shared Decision-Making in Prostate Cancer Management: Easy to Say, Hard to Measure.
    J Urol. 2026;215:349-350.
    PubMed        
    
    
22. WASSERSUG R
    Letter: Shared Decision-Making in Prostate Cancer Management: Easy to Say, Hard to Measure.
    J Urol. 2026;215:350-351.
    PubMed        
    
    
23. VICKERS AJ, Wallis CJD, Touijer K
    Decision Analysis of Pelvic Lymph Node Dissection During Radical Prostatectomy.
    J Urol. 2026;215:276-285.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

24. NILSSON P, Gunnlaugsson A, Beckman L, Widmark A, et al
    Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial.
    Lancet Oncol. 2026 Feb 5:S1470-2045(25)00656.
    PubMed         Abstract available
    
    

    
    Mod Pathol

25. SERAFIN RB, Lopez JS, Chow S, Wang R, et al
    Detection of prostate cancer in 3D pathology datasets via generative immunolabeling.
    Mod Pathol. 2026 Feb 13:100975. doi: 10.1016/j.modpat.2026.100975.
    PubMed         Abstract available
    
    

    
    Nat Rev Urol

26. LEUNG DHL, Adzavon YM, Chu G, Park TJ, et al
    ADT and activation of HGF and WNT axes in double-null prostate cancer.
    Nat Rev Urol. 2026 Feb 9. doi: 10.1038/s41585-026-01129.
    PubMed         Abstract available
    
    

    
    PLoS One

27. 
    Retraction: Molecular mechanism of inhibitory effects of melatonin on prostate cancer cell proliferation, migration and invasion.
    PLoS One. 2026;21:e0342720.
    PubMed        
    
    

    
    Prostate

28. WEI L, Wang Z, Gao D, Ge J, et al
    Loss of GPR133 Promotes Enzalutamide Resistance in Prostate Cancer by Upregulating HSD3B1 and Intratumoral Androgen Synthesis.
    Prostate. 2026 Feb 10. doi: 10.1002/pros.70138.
    PubMed         Abstract available
    
    
29. SWAMI U, Shao Q, Alfred T, Touya M, et al
    Corticosteroid Use and Risk of Adverse Events in Metastatic Hormone-Sensitive Prostate Cancer.
    Prostate. 2026 Feb 10. doi: 10.1002/pros.70143.
    PubMed         Abstract available
    
    
30. SHARMA A, Sudan SK, Khan MA, Tahir M, et al
    Smoking Behavior Is Associated With an Altered Immune Landscape in Prostate Cancer: Implications for Patient Outcomes.
    Prostate. 2026 Feb 10. doi: 10.1002/pros.70142.
    PubMed         Abstract available
    
    

    
    Radiol Imaging Cancer

31. NIKANPOUR Y, Singh Y
    Impact of Upfront PSMA PET/CT Staging on Real-World Treatment Selection in High-Risk Prostate Cancer.
    Radiol Imaging Cancer. 2026;8:e269002.
    PubMed        
    
    

    
    Urology

32. SONG JJ, Lee SZ, Zhou MT, Jones JM, et al
    Smoking and Surgical Complications Following Robotic-assisted Laparoscopic Radical Prostatectomy: A NSQIP Analysis.
    Urology. 2026;208:106-111.
    PubMed         Abstract available
    
    
33. REZAEE ME, Meeks W, Galen E, Helsel A, et al
    Examining Variation in Prostate Biopsy Practices in the United States: An Analysis of American Urological Association Census Data.
    Urology. 2026;208:9-13.
    PubMed         Abstract available
    
    
34. SCHMEUSSER BN, Zappia JL, Edwards KR, Adaniya KH, et al
    Reliability of Prostate Imaging-reporting and Data System Scoring Following Holmium Laser Enucleation of Prostate.
    Urology. 2026;208:91-95.
    PubMed         Abstract available
    
    
35. LENG L, Maremanda A, Li KD, Pace WA, et al
    Genitourinary Radiation Injury: A Mixed-methods Study Exploring Patient-reported Outcomes and Impact on Quality of Life.
    Urology. 2026;208:59-66.
    PubMed         Abstract available
    
    
36. XIAO B, Qian Z, Look-Why SL, Piccolini A, et al
    Prostate Biopsy and Malpractice: Analysis of a National Legal Database from 1995 to 2025.
    Urology. 2026;208:117-123.
    PubMed         Abstract available
    
    
37. HOLZBEIERLEIN H, Kundu N, Handa N, Jang JW, et al
    Performance of the Prostate Health Index Test in Men With Prostate Specific Antigen Levels Between 10 and 20 ng/mL.
    Urology. 2026;208:112-116.
    PubMed         Abstract available
    
    
38. DEMASI M, Evans A, Syphan T, Murphy J, et al
    Divergent Trends in PSA Screening Prior to Testosterone Therapy in Younger vs. Older Men Amidst Shifting Guidelines.
    Urology. 2025 Dec 22:S0090-4295(25)01399-8. doi: 10.1016/j.urology.2025.
    PubMed         Abstract available
    
    
39. COCKRUM J, Monda S
    Editorial Comment on "Homologous Recombination Repair Mutations, Next-Generation Sequencing Testing, and Treatment Progression by Race Among Patients with Metastatic Castration-Sensitive Prostate Cancer".
    Urology. 2026 Feb 13:S0090-4295(26)00102-0. doi: 10.1016/j.urology.2026.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum